|
|
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum
|
|
|
T2 Biosystems Announces Third Quarter 2020 Financial Results
|
|
|
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
|
|
|
T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020
|
|
|
T2 Biosystems Announces BARDA Exercise of Contract Option 1 Valued at $10.5 Million
|
|
|
T2 Biosystems to Participate in Sepsis Alliance Summit
|
|
|
T2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year
|
|
|
T2 Biosystems Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test
|
|
|
T2 Biosystems Announces Second Quarter 2020 Financial Results
|
|
|
T2 Biosystems Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split
|
